Centessa Pharmaceuticals PLC CNTA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:30 PM EDT
8.61quote price arrow down-0.11 (-1.26%)
Volume
245,948
52 week range
3.96 - 12.45
Loading...
  • Open8.70
  • Day High8.70
  • Day Low8.50
  • Prev Close8.72
  • 52 Week High12.45
  • 52 Week High Date03/22/24
  • 52 Week Low3.96
  • 52 Week Low Date05/25/23

Key Stats

  • Market Cap970.313M
  • Shares Out112.70M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.45
  • YTD % Change8.04

KEY STATS

  • Open8.70
  • Day High8.70
  • Day Low8.50
  • Prev Close8.72
  • 52 Week High12.45
  • 52 Week High Date03/22/24
  • 52 Week Low3.96
  • 52 Week Low Date05/25/23
  • Market Cap970.313M
  • Shares Out112.70M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.45
  • YTD % Change8.04

RATIOS/PROFITABILITY

  • EPS (TTM)-1.42
  • P/E (TTM)-6.07
  • Fwd P/E (NTM)-5.07
  • EBITDA (TTM)-157.535M
  • ROE (TTM)-54.45%
  • Revenue (TTM)6.853M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-2,019.80%
  • Debt To Equity (MRQ)35.69%

EVENTS

  • Earnings Date08/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Centessa Pharmaceuticals PLC

 

Profile

MORE
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for...
Francesco de Rubertis Ph.D.
Independent Chairman of the Board
Saurabh Saha M.D., Ph.D
Chief Executive Officer, Director
Gregory Weinhoff M.D.
Chief Financial Officer
Antoine Yver M.D.
Executive Vice President and Chairman of Development
Address
3Rd Floor, 1 Ashley Road
Altrincham
WA14 2DT
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
SRRK
Scholar Rock Holding Corp
12.07-0.45-3.59%
CATX
Perspective Therapeutics Inc
1.54-0.08-5.21%
CATX
Perspective Therapeutics Inc
1.54-0.08-5.21%
LQDA
Liquidia Corp
13.11-0.24-1.80%
TYRA
Tyra Biosciences Inc
18.31-0.41-2.17%